0.00Open0.20Pre Close0 Volume0 Open Interest1.50Strike Price0.00Turnover0.00%IV-3.17%PremiumJan 17, 2025Expiry Date0.24Intrinsic Value100Multiplier-6DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma6.30Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Tenaya Therapeutics Stock Discussion
Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones
Monday, 13th January at 9:16 am
Continued Focus on Driving Advancement of TN-201 and TN-401 Gene Therapies for Cardiomyopathies
Dosing Initiated in Cohort 2 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy
Additional Cohort 1 Data to be Reported in 1H25 Building on Promising Initial Data
Initial Data from RIDG...
No comment yet